American Society of Hematology

ASH is the leader in representing the interests of scientists and clinicians working in the field of hematology on Capitol Hill and within federal agencies concerned with the study and treatment of blood-related diseases.


SCD Initiative 

Sickle Cell Disease Initiative

A multi-faceted initiative to identify the highest priority actions needed to improve the outcomes for individuals with SCD in the U.S. and globally.

Fight for Hematology 

Support Medical Research

Urge your members of Congress to support continued medial research funding.

Advocacy Leadership Institute

Provides opportunities to learn more about advocacy, health policy, and the legislative process, and to become engaged in the Society’s activities.

Congressional Fellowship

Provides education about the policy making process, including Congress’ relationship to the hematology community.

MACRA Resources

Get an overview of the Medicare Access and CHIP Reauthorization Act (MACRA) and its impact on hematology.

Drug Access Issues

Keep informed of newly approved therapies, safety and prescription matters, and shortages of critical hematologic drugs.

CAC Networking Meeting

Learn about the yearly ASH-ASCO Carrier Advisory Committee (CAC) Network Meeting.

  • Contact Congress in Support of Sustained and Predictable Funding for NIH

    ASH has strongly urged Congress to provide increased funding for NIH. Flat or reduced funding for NIH would delay progress and prevent valuable research from turning into tomorrow’s cures. As the legislation makes its way through Congress, it’s important that your representatives hear from you about why biomedical research is important to you and the patients that you treat.

  • Contact Your Senators in Support of Sickle Cell Disease Legislation

    Legislation to help improve outcomes for patients suffering from sickle cell disease (SCD) has successfully passed out of the House of Representatives and companion legislation has been introduced in the Senate. The Sickle Cell Disease Surveillance, Prevention, and Treatment Act of 2018 aims to improve understanding of health care system utilization patterns of people with SCD and establish cost-effective practices to improve and extend the lives of patients.

  • Urge your Representative to Support the Cancer Drug Parity Act

    Legislation has been introduced in the U.S. House of Representatives that would ensure that patients enrolled in certain federally regulated health plans have access and insurance coverage for all anti-cancer regimens. Your Representative needs to cosponsor these bills in order for them to be considered by the full Congress.

  • Contact Your Michigan House Member to Support HB 5367

    Legislation has been introduced in the Michigan House of Representatives that would ensure that patients have access and insurance coverage for all anti-cancer regimens regardless of the form that they take.

View all action alerts
  • CMS Releases National Coverage Determination on Next Generation Sequencing

    CMS released a National Coverage Determination entitled Next Generation Sequencing for Medicare Beneficiaries with Advanced Cancer. ASH submitted comments on the proposal along with over 300 other groups, including physician specialty societies, patient advocacy groups, and industry groups.

  • ASH Applauds the Sickle Cell Disease Surveillance, Prevention, and Treatment Act of 2018

    Senators Tim Scott (R-SC) and Cory Booker (D-NJ) introduced the Sickle Cell Disease Surveillance, Prevention, and Treatment Act of 2018.

  • Update on Tax Reform

    On December 20, the House of Representatives and the Senate voted to approve H.R. 1, tax reform legislation. Select members of each chamber came together to resolve disagreements between the two versions passed by the House and Senate.

  • 2017 Action of the Affordable Care Act

    Congress spent much of 2017 focused on the repeal and replace of the Affordable Care Act (ACA). Included is a summary of Congress and the Administration’s actions on repeal and replace of the ACA that occurred in 2017.

View all policy news
back to top